Agenus Inc. , a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, LAG-3, and others. In addition, the company develops vaccine programs, including Prophage cancer vaccine candidate; AutoSynVax, a synthetic neo-antigen; and PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neo-epitopes. Further, it develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. Additionally, the company engages in the development of CTLA-4 and PD-1 antagonists; and anti-CTLA-4, CD137, and anti-TIGIT antibodies, as well as various multi-specific antibodies that are under various stages of development. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA.; collaboration with Gilead Sciences, Inc. to develop immuno-oncology therapies; and partnership with Phyton Biotech. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

  • Agenus Appoints Don Vidic as Vice President and Head of Commercial
    on July 18, 2019 at 6:00 pm

    LEXINGTON, Mass., July 18, 2019 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology company with a broad pipeline of novel clinical and preclinical stage checkpoint antibodies, cell therapies and neoantigen vaccines, today announced the appointment of Don Vidic as Vice President, Head of Commercial. "Don has deep expertise in market access and distribution strategies and shares our commitment to disruptive commercial models designed to provide access to all patients who need our products," said Garo H. Armen, Ph.D., Chairman and CEO of Agenus. "We have built a unique ecosystem which has allowed us to innovate with speed and set new records in drug discovery and development.  We are on track to submit our first BLA filing for our lead CTLA-4 and PD-1 molecules in 2020. […]

  • Agenus (AGEN) Upgraded to Buy: What Does It Mean for the Stock?
    on July 8, 2019 at 1:00 pm

    Agenus (AGEN) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. […]

  • Gilead Inks Deal With Carna Biosciences for Immuno-Oncology
    on June 26, 2019 at 10:24 am

    Gilead (GILD) teams up with Carna Biosciences to develop and commercialize small molecule compounds in immuno-oncology. […]

  • How Many Agenus Inc. (NASDAQ:AGEN) Shares Do Institutions Own?
    on June 20, 2019 at 1:36 pm

    If you want to know who really controls Agenus Inc. (NASDAQ:AGEN), then you'll have to look at the makeup of its share... […]

  • Gilead (GILD) Teams Up With Nurix for Cancer and Other Drugs
    on June 20, 2019 at 10:33 am

    Gilead (GILD) collaborates with Nurix Therapeutics to leverage the proprietary drug discovery platform of the latter to identify novel agents that induce degradation of specified drug targets. […]

  • Agenus to Host Annual Meeting of Stockholders
    on June 13, 2019 at 7:48 pm

    LEXINGTON, Mass. , June 13, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies ... […]

  • Edited Transcript of AGEN earnings conference call or presentation 9-May-19 12:30pm GMT
    on June 11, 2019 at 7:44 pm

    Q1 2019 Agenus Inc Earnings Ca […]

  • Why Is Agenus (AGEN) Down 6.3% Since Last Earnings Report?
    on June 8, 2019 at 1:31 pm

    Agenus (AGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. […]

  • MiMedx Announces Comprehensive Board Refreshment Plan in Cooperation with Prescience Point
    on May 30, 2019 at 12:00 pm

    MARIETTA, Ga., May 30, 2019 /PRNewswire/ -- MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or the "Company"), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced that the Company's board of directors (the "Board") has adopted a comprehensive plan to refresh the composition of the Board. The plan was developed by the Board in cooperation with one of the Company's largest shareholders, Prescience Point Capital Management LLC ("Prescience Point"), and follows the completion of the Audit Committee's independent investigation into alleged wrongdoing by the prior senior management team and the engagement of BDO USA, LLP as the Company's new independent registered public accounting firm. […]

  • Agenus' (AGEN) Pipeline Progression on Track Amid Competition
    on May 24, 2019 at 2:53 pm

    Agenus (AGEN) is developing its pipeline candidates and has an array of collaboration contracts to its credit that bodes well for growth. […]

Welcome Don Vidic as Head of Commercial. Don is an innovator & expert in market access & distribution. He joins to actualize our commitment to disruptive commercial models designed to provide access to all patients who need our products.

The PM of Armenia is setting a new standard for leadership and integrity. COAF is working to empower the village children.

Our newsletter sums our differentiation $AGEN. At an inflection ' me this defines Agenus, not a molecule [or] platform, but convergence allowing us to look at & treat cancer in a new & extraordinary way’ @johnnosta. #immunotherapy #cancerresearch

$AGEN next newsletter issues on Monday (08JUL) with highlights from our annual shareholder meeting & a special feature from visionary @JohnNosta #HappyFourthOfJuly

We are thrilled to welcome top health technology theorist & industry leader @JohnNosta to facilitate our Annual General Meeting tomorrow. We will provide exciting updates on our progress! See press release for meeting details:
#oncology #cancer #innovation

Load More...

    Feed has no items.


What's Your Role?*



Company Description*



Agenus Inc.

3 Forbes Road
Lexington, MA 02421

+1 (781) 674-4400

July 2019
« Apr    

©2019 ALIGNMT LLC | Alignment Consulting | Mergers & Acquisitions | Investor Relations


We're not around right now. But you can send us an email and we'll get back to you, asap.


Log in with your credentials


Forgot your details?

Create Account